Journals Progress in Neuro-psychopharma...

Progress in Neuro-psychopharmacology & Biological Psychiatry
Ming-Yuan Tian, Xin-Yi Zhou, Xiao-Yuan Liao, Ke Gong, Xiao-Tong Cheng, Cheng Qin, Ke-Zhi Liu, Jing Chen, Wei Lei
AIMS: This study aimed to identify gray/white matter volume (GMV/WMV) alterations in IGD, with a special focus on the subregions of the mesocorticolimbic dopaminergic system and their clinical association. RESULTS: Compared with HCs, IGDs showed bigger GMV in the bilateral caudate and the left nucleus accumbens (NAc), and bigger WMV in the inferior parietal lobule. ROI-wise comparisons confirmed increased GMV in bilateral caudate (including the dorsal anterior, body, and tail) and the left core of NAc in IGD, but no significant WMV alterations in the mesocorticolimbic dopaminergic system...
June 2, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Leora Pearl-Dowler, Luca Posa, Martha Lopez-Canul, Alexandra Teggin, Gabriella Gobbi
Neuropathic pain (NP) is often treated with opioids, the prolonged use of which causes tolerance to their analgesic effect and can potentially cause death by overdose. The phytocannabinoid delta-9-tetrahydrocannabinol (THC) may be an effective alternative analgesic to treat NP in morphine-tolerant subjects. Male Wistar rats developed NP after spared nerve injury, and were then treated with increasing doses of THC (1, 1.5, 2, 2.5, and 5 mg/kg, intraperitoneally) which reduced mechanical allodynia at the dose of 2...
May 29, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Da-Wei Zhang, Stuart J Johnstone, Bruno Sauce, Martijn Arns, Li Sun, Han Jiang
Improving neurocognitive functions through remote interventions has been a promising approach to developing new treatments for attention-deficit/hyperactivity disorder (AD/HD). Remote neurocognitive interventions may address the shortcomings of the current prevailing pharmacological therapies for AD/HD, e.g., side effects and access barriers. Here we review the current options for remote neurocognitive interventions to reduce AD/HD symptoms, including cognitive training, EEG neurofeedback training, transcranial electrical stimulation, and external cranial nerve stimulation...
May 29, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Natasa Hlavacova, Katarina Hrivikova, Lucia Karailievova, Peter Karailiev, Judith R Homberg, Daniela Jezova
Chronic stress is a key factor in psychiatric and neurological disorders often worsening disease symptoms. In this study, a unique animal model, the dopamine transporter knockout (DAT-KO) rat exhibiting behavioral signs resembling those occurring in mania, schizophrenia, attention deficit hyperactivity disorder, and obsessive-compulsive disorder was used. We have tested the hypothesis that the hyperdopaminergic state in DAT-KO rats (i) modulates behavioral response to the NMDA antagonist MK-801 (dizocilpine) and (ii) leads to abnormal endocrine and immune activation under subchronic stress induced by an immune challenge...
May 27, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Frédéric Briend, Laurent Barantin, Helen Cléry, Jean-Philippe Cottier, Frédérique Bonnet-Brilhault, Emmanuelle Houy-Durand, Marie Gomot
BACKGROUND: The neurobiology of Autism Spectrum Disorder (ASD) is still unknown. Alteration in glutamate metabolism might translate into an imbalance of the excitation/inhibition equilibrium of cortical networks that in turn are related to autistic symptoms, but previous studies using voxel located in bilateral anterior cingulate cortex (ACC) failed to show abnormalities in total glutamate level. Due to the functional differences in the right and left ACC, we sought to determine whether a difference between right and left ACC glutamate levels could be found when comparing ASD patients and control subjects...
May 26, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Robyn M Brown, Sarah S Ch'ng, Caroline C Davis
No abstract text is available yet for this article.
May 26, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Clement C Zai, Alessio Squassina, Arun K Tiwari, Claudia Pisanu, Marco Pinna, Federica Pinna, Anna Meloni, Pasquale Paribello, Bernardo Carpiniello, Leonardo Tondo, Mark A Frye, Joanna M Biernacka, Brandon J Coombes, James L Kennedy, Mirko Manchia
Antidepressant-induced mania (AIM) is a side effect of antidepressant treatment that is characterized by mania or hypomania after the start of medication. It is likely polygenic, but its genetic component remains largely unexplored. We aim to conduct the first genome-wide association study of AIM in 814 bipolar disorder patients of European ancestry. We report no significant findings from our single-marker or gene-based analyses. Our polygenic risk score analyses also did not yield significant results with bipolar disorder, antidepressant response, or lithium response...
May 24, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Wen-Jun Su, Jia-Mei Li, Ting Zhang, Zhi-Yong Cao, Ting Hu, Shi-Yang Zhong, Zhang-Yang Xu, Hong Gong, Chun-Lei Jiang
BACKGROUND: Abundant evidence suggests that the prevalence and risk of depression in people with diabetes is high. However, the pathogenesis of diabetes-related depression remains unclear. Since neuroinflammation is associated with the pathophysiology of diabetic complications and depression, this study aims to elucidate the neuroimmune mechanism of diabetes-related depression. METHODS: Male C57BL/6 mice were injected with streptozotocin to establish a diabetes model...
May 18, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Rita Vieira, Ana Raquel Faria, Diogo Ribeiro, Maria Picó-Pérez, João M Bessa
Identifying and integrating the neural correlates of suicidal ideation and behaviors is crucial to expand the knowledge and develop targeted strategies to prevent suicide. This review aimed to describe the neural correlates of suicidal ideation, behavior and the transition between them, using different magnetic resonance imaging (MRI) modalities, providing an up-to-date overview of the literature. To be included, the observational, experimental, or quasi-experimental studies must include adult patients currently diagnosed with major depressive disorder and investigate the neural correlates of suicidal ideation, behavior and/or the transition using MRI...
May 17, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
David D Kim, Ric M Procyshyn, Andrea A Jones, Lik Hang N Lee, William J Panenka, Jacob L Stubbs, Lianne L Cho, Olga Leonova, Kristina Gicas, Allen E Thornton, Donna J Lang, G William MacEwan, William G Honer, Alasdair M Barr
OBJECTIVE: Many individuals living in precarious housing or homelessness have multimorbid illnesses, including substance use, psychiatric, and neurological disorders. Movement disorders (MDs) associated substance use are amongst the poorly studied subtopics of drug-induced MDs. The aim of the present study was, therefore, to determine the proportion affected and severity of different signs of MDs, as well as their associations with substance use in a community-based sample of precariously housed and homeless individuals...
May 15, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Esra Toplu Uslu, Murat Mengi, Elmas Beyazyüz, Aliye Çelikkol, Yakup Albayrak
Tardive dyskinesia (TD) is a persistent involuntary complex movement disorder that is known to occur with long-term antipsychotic treatment. Despite being a well-recognized complication of this treatment, its symptoms are often masked by the antipsychotic agents, only to become apparent upon reducing or terminating the treatment. In an effort to advance our understanding of TD pathophysiology and to identify potential therapies, the current study aimed to establish an animal model of TD by administering haloperidol to rats and to evaluate the efficacy of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), in ameliorating TD symptoms...
May 15, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Jiahui Yin, Rongpeng Gong, Min Zhang, Lei Ding, Ting Shen, Yiyun Cai, Shen He, Daihui Peng
Both depression and sleep disturbance have been linked to inflammation. However, the role that inflammation plays in the relationship between sleep disturbance and depression remains unclear. We examined pairwise associations between inflammatory markers (neutrophil-to-lymphocyte ratio [NLR] and C-reactive protein level [CRP]), sleep disturbance, and depressive symptoms in a robust, ethnically diverse sample (n = 32,749) from the National Health and Nutrition Examination Survey (NHANES). We found higher levels of inflammatory markers in participants with depression and/or sleep disturbance compared to those without depression or sleep disturbance...
May 11, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
David Quispe Escudero
D1-like receptors have two important qualities, they are all metabotropic and they activate with phasic dopamine. After analyzing the molecular implications of each of these qualities separately and then combining them for the specific case of the prefrontal cortex, we propose a model that explains why long term potentiation in this cortical area depends on the amount of contact between D1-like receptors and dopamine. This simple model also explains why in order to promote long term potentiation, dopamine transporters should be scarce in the prefrontal cortex...
May 9, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Chune Li, Shiqiang Cheng, Yujing Chen, Yumeng Jia, Yan Wen, Huijie Zhang, Chuyu Pan, Jingxi Zhang, Zhen Zhang, Xuena Yang, Peilin Meng, Yao Yao, Feng Zhang
BACKGROUND: Previous genetic studies of anxiety and depression were mostly based on independent phenotypes. This study aims to investigate the shared and specific genetic structure between anxiety and depression. METHOD: To identify the underlying factors of Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), and their combined scale (joint scale), we employed exploratory factor analysis (EFA) using the eigenvalue of parallel analysis...
May 8, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Zihao Yang, David Li, Ying He, Xiaogang Chen, Zongchang Li
Longitudinal observational studies and Mendelian randomization research have obtained contradictory conclusions regarding the association between C-reactive protein (CRP) level and schizophrenia risk. However, the shared genetic mechanisms underlying CRP and schizophrenia remain poorly understood. Here, we examined the global and local genetic correlations using summary statistics from large-scale genome-wide association studies (GWAS) on CRP level and schizophrenia. Furthermore, we identified their shared genetic variants by applying the conditional false discovery rate approach and performed functional analyses of shared variants to explore the shared genetic mechanisms underlying CRP level and schizophrenia...
May 5, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Nanako Nakama, Noriyoshi Usui, Miyuki Doi, Shoichi Shimada
In recent years, it has become known that stress in childhood, called early life stress (ELS), affects the mental health of children, adolescents, and adults. Child maltreatment (CM) is an inappropriate form of childcare that interferes with children's normal brain and mind development. Previous studies have reported that CM severely affects brain development and function. For example, ELS causes brain vulnerability and increases the risk of developing psychiatric disorders. In addition, it is known that the different types and timing of abuse have different effects on the brain...
May 4, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Leandro Val Sayson, Hyun Jun Lee, Darlene Mae Ortiz, Mikyung Kim, Raly James Perez Custodio, Chae Hyeon Lee, Yong Sup Lee, Jae Hoon Cheong, Hee Jin Kim
With the pervasive occurrence of substance abuse worldwide, unraveling the neuropharmacology of drugs of abuse, such as psychostimulants, is undeniably essential. Mice lacking Period 2 (Per2), a gene associated with the biological time-regulating system or circadian rhythm, have been proposed as a potential animal model for drug abuse vulnerability, demonstrating a greater preference for methamphetamine (METH) reward than wild-type (WT) mice. However, the responses of Per2 knockout (KO) mice to the reinforcing effects of METH or other psychostimulants are yet to be established...
May 2, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Mengqing Xia, Yingchan Wang, Wenjun Su, Yingying Tang, Tianhong Zhang, Huiru Cui, Yanyan Wei, Xiaochen Tang, Lihua Xu, Hao Hu, Qian Guo, Zhenying Qian, Xuming Wu, Chunbo Li, Jijun Wang
BACKGROUND: Antipsychotic treatment has been shown to yield hippocampal and amygdalar volumetric changes in first-episode schizophrenia (FES). However, whether antipsychotic induced volumetric changes interact with age remains unclear. METHODS: The current study includes data from 120 medication naïve FES patients and 110 matched healthy controls (HC). Patients underwent MRI scans before (T1) and after (T2) antipsychotic treatment. HCs underwent MRI scans at baseline only...
May 2, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Marie-Claire Davis, Aron T Hill, Paul B Fitzgerald, Neil W Bailey, Caley Sullivan, Julie C Stout, Kate E Hoy
We investigated the effects of transcranial alternating current stimulation (tACS) targeted to the bilateral medial prefrontal cortex (mPFC) and administered at either delta or alpha frequencies, on brain activity and apathy in people with Huntington's disease (HD) (n = 17). Given the novelty of the protocol, neurotypical controls (n = 20) were also recruited. All participants underwent three 20-min sessions of tACS; one session at alpha frequency (Individualised Alpha Frequency (IAF), or 10 Hz when an IAF was not detected); one session at delta frequency (2 Hz); and a session of sham tACS...
April 27, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Guillaume Fond, Mélanie Faugere, Laurent Boyer, Pauline Peri, Florian Stephan, Fanny Moliere, Loic Anguill, Djamila Bennabi, Emmanuel Haffen, Alexandra Bouvard, Michel Walter, Ludovic Samalin, Pierre Michel Llorca, Jean Baptiste Genty, Marion Leboyer, Jérôme Holtzmann, Anne Sophie Nguon, Romain Rey, Mathilde Horn, Guillaume Vaiva, Vincent Hennion, Bruno Etain, Wissam El-Hage, Vincent Camus, Philippe Courtet, Bruno Aouizerate, Antoine Yrondi, Christophe Lancon, Raphaelle Richieri
BACKGROUND: Benzodiazepine long-term use (BLTU) is a public health challenge. We lack data on the consequences of LBTU on the trajectory of treatment-resistant depression (TRD). OBJECTIVE: To determine the prevalence of BLTU in a nationwide non-selected population of patients with TRD, to determine the rate of patients succeeding at withdrawing benzodiazepines at one year and to determine if persistent BLTU is associated with poorer mental health outcomes. METHOD: The FACE-TRD cohort is a national cohort of TRD patients recruited in 13 resistant depression expert centers between 2014 and 2021 and followed-up at one year...
April 27, 2023: Progress in Neuro-psychopharmacology & Biological Psychiatry
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.